These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 1345462)
1. Effect of choriocarcinoma supernatant on natural killer and lymphokine-activated killer cell activity. Fülöp V; Szigetvári I; Szepesi J; Gáti I Acta Med Hung; 1992-1993; 49(3-4):239-47. PubMed ID: 1345462 [TBL] [Abstract][Full Text] [Related]
2. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells. Midis GP; Gupta VK; Fabian DF; Lefor AT J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171 [TBL] [Abstract][Full Text] [Related]
3. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann GG; Zeuthen J; Claësson MH Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282 [TBL] [Abstract][Full Text] [Related]
4. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Komiyama A; Kawai H; Yabuhara A; Yanagisawa M; Miyagawa Y; Ota M; Hasekura H; Akabane T Pediatrics; 1990 Mar; 85(3):323-30. PubMed ID: 2304785 [TBL] [Abstract][Full Text] [Related]
5. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
6. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry. Callewaert DM; Radcliff G; Waite R; LeFevre J; Poulik MD Cytometry; 1991; 12(7):666-76. PubMed ID: 1782834 [TBL] [Abstract][Full Text] [Related]
7. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts. Dannemann BR; Morris VA; Araujo FG; Remington JS J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453 [TBL] [Abstract][Full Text] [Related]
8. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
9. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. Naume B; Shalaby R; Lesslauer W; Espevik T J Immunol; 1991 May; 146(9):3045-8. PubMed ID: 1707931 [TBL] [Abstract][Full Text] [Related]
10. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Gunji Y; Lewis J; Gorelik E Blood Coagul Fibrinolysis; 1990 Dec; 1(6):663-72. PubMed ID: 2133246 [TBL] [Abstract][Full Text] [Related]
11. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
12. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512 [TBL] [Abstract][Full Text] [Related]
13. A novel telomerase-based approach to detect natural cell-mediated cytotoxic activity against tumor cells in vitro. Faraoni I; Cottarelli A; Giuliani A; Bonmassar L; Rossi L; Bonmassar E J Immunol Methods; 2005 Oct; 305(2):162-72. PubMed ID: 16165149 [TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989 [TBL] [Abstract][Full Text] [Related]
15. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
16. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Komatsu F; Kajiwara M Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151 [TBL] [Abstract][Full Text] [Related]
17. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
18. Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor. Wright SC; Bonavida B J Immunol; 1987 Mar; 138(6):1791-8. PubMed ID: 3493288 [TBL] [Abstract][Full Text] [Related]
19. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Mizutani Y; Bonavida B; Nio Y; Yoshida O Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609 [TBL] [Abstract][Full Text] [Related]
20. Generation of a lipid-like cytotoxin from human CD16+ natural killer cells. Cosentino LM; Cathcart MK Cancer Res; 1989 Dec; 49(23):6662-9. PubMed ID: 2531033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]